CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Go back to CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)| (NASDAQ: CRVO) | Delayed: 2.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.86 | 52 Week High | $ | |||
| Open | $2.86 | 52 Week Low | $ | |||
| Day High | $2.86 | P/E | N/A | |||
| Day Low | $2.86 | EPS | $ | |||
| Volume | 8,337 | |||||
